BioSpace News Archive

MapLight Therapeutics, a clinical-stage biopharmaceutical company working to develop targeted novel therapeutics to improve the lives of patients suffering from debilitating CNS disorders, announced the appointment of Vishwas Setia as Chief Financial Officer.

The Alzheimer’s Therapeutic Research Institute and over a half-dozen of San Diego’s Alzheimer’s partners invite the community to a free event on March 23, 2024.

Award Recognizes Exceptional Contributions by Women in the Life Sciences Industry

Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the “Company” or “Sona”) announces that it has submitted a provisional patent application with the United States Patent and Trademark Office (USPTO), for its proprietary photothermal light device, entitled, “ENDOSCOPE WITH EMR OPTICAL FIBER AND THERMAL SENSOR FOR PHOTOTHERMAL THERAPY”.

American Aires Inc. (CSE: WIFI) (OTC Pink: AAIRF) (“Aires” or the “Company”), a pioneer in cutting-edge technology designed to protect against electromagnetic radiation and optimize human health, is excited to announce a strategic partnership with William Morris Endeavor Entertainment, LLC (“WME”), a titan in entertainment, sports, and fashion.

RS BioTherapeutics is pleased to announce that its submission has been selected for a poster presentation at the 2024 Respiratory Innovation Summit hosted by the American Thoracic Society (ATS).

SCHOTT Pharma plans to make Wilson, North Carolina home to its newest site. The investment is supported by $21 million in state and local incentive awards and will expand SCHOTT Group’s presence in the United States, a strategic market in its growth plan.

New research finds that C₂N Diagnostics, LLC’s proprietary algorithm used in its PrecivityAD2 blood test, which is used by healthcare providers to determine Alzheimer’s disease (AD) pathology in individuals with early cognitive impairment, can identify brain amyloid status with “sensitivity, specificity, positive and negative predictive values that approximate those of amyloid positron emission tomography (PET) imaging.”

Today, the U.S. Food and Drug Administration approved Lenmeldy (atidarsagene autotemcel), the first FDA-approved gene therapy indicated for the treatment of children with pre-symptomatic late infantile, pre-symptomatic early juvenile or early symptomatic early juvenile metachromatic leukodystrophy (MLD).

Today, Nexus Pharmaceuticals announced the launch of Baclofen Injection, USP.